Primary Sclerosing Cholangitis Growth Trends, Report Overview Analysis 2019

Posted on 2019-10-01 by Mark Hub in Pharmaceuticals // 0 Comments

Albany, US, 2019-Oct-01 — /EPR Network/ —This research report titled “Primary Sclerosing Cholangitis-Pipeline Review, H2 2019” has been added to the wide online database managed by Market Research Hub (MRH). The study discusses the prime market growth factors along with future projections expected to impact the Primary Sclerosing Cholangitis during the period 2019. The concerned sector is analyzed based on different market factors including drivers, restraints and opportunities in order to enlighten the readers about the actual scenario prevailing in the Primary Sclerosing Cholangitis

Get Sample Copy@ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2519482

Primary Sclerosing Cholangitis – Pipeline Review, H2 2019

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Primary Sclerosing Cholangitis – Pipeline Review, H2 2019, provides an overview of the Primary Sclerosing Cholangitis (Gastrointestinal) pipeline landscape.

Primary sclerosing cholangitis (PSC) is a chronic liver disease characterized by a progressive course of cholestasis with inflammation and fibrosis of the intrahepatic and extra hepatic bile ducts. Symptoms include abdominal pain, chills, diarrhea, fatigue, itchiness and weight loss. The predisposing factors include age and inflammatory bowel diseases. Treatment includes antibiotics and bile-acid-binding drugs.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Primary Sclerosing Cholangitis – Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Primary Sclerosing Cholangitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Primary Sclerosing Cholangitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Primary Sclerosing Cholangitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 7, 4, 1, 11 and 1 respectively.

Primary Sclerosing Cholangitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Primary Sclerosing Cholangitis (Gastrointestinal).
– The pipeline guide reviews pipeline therapeutics for Primary Sclerosing Cholangitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Primary Sclerosing Cholangitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Primary Sclerosing Cholangitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Primary Sclerosing Cholangitis (Gastrointestinal)

Reasons to buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Primary Sclerosing Cholangitis (Gastrointestinal).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Primary Sclerosing Cholangitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Request TOC of the Report @ https://www.marketresearchhub.com/report/primary-sclerosing-cholangitis-pipeline-review-h2-2019-report.html

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Primary Sclerosing Cholangitis – Overview
Primary Sclerosing Cholangitis – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Primary Sclerosing Cholangitis – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Primary Sclerosing Cholangitis – Companies Involved in Therapeutics Development
Albireo Pharma Inc
Allergan Plc
CymaBay Therapeutics Inc
Dr. Falk Pharma GmbH
Gilead Sciences Inc
Immunic Inc
Intercept Pharmaceuticals Inc
Morphic Holding Inc
NGM Biopharmaceuticals Inc
Nyrada Inc
Pliant Therapeutics Inc
Seres Therapeutics Inc
Shenzhen HighTide Biopharmaceutical Ltd
Sirnaomics Inc
Takeda Pharmaceutical Co Ltd
Primary Sclerosing Cholangitis – Drug Profiles
berberine ursodeoxycholate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologics for Liver Diseases – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bulevirtide – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BX-003 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cenicriviroc – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cilofexor – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CM-101 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HTD-1801 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMU-838 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NGM-282 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
norursodeoxycholic acid – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NYX-205 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
obeticholic acid – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
odevixibat – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PLN-1177 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PLN-1561 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PLN-1705 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PLN-74809 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
QBT-002 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
QBT-006 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SC-435 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
seladelpar lysine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize Integrin Alpha 5 and Beta 6 for Non-Alcoholic Steatohepatitis and Primary Sclerosing Cholangitis – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Autoimmune Hepatitis and Primary Sclerosing Cholangitis – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STP-705 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
volixibat potassium – Drug Profile
Product Description
Mechanism Of Action

Enquire about This Report @ https://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=2519482

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports of different sector like Pharmaceuticals market research and analysis. MRH’s expansive collection of industry reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Matched content

Editor’s pick